MDxHealth SA (MDXH) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several concerning factors: a widening operating loss, a significant net loss, and a decrease in cash reserves. Although management expressed confidence in their core business and provided optimistic guidance, the Q&A highlighted unresolved financial issues and vague responses from management. These factors, combined with the absence of strong positive catalysts, suggest a negative sentiment, likely resulting in a stock price decline of -2% to -8% over the next two weeks.
Key Financial Performance
Revenue As reported revenue for Q1 2026 was $27.4 million. On a pro forma basis, excluding the Resolve business, revenues for core prostate cancer operations increased by 11% to $23.9 million. This growth demonstrates the continued commercial execution of the integrated sales team.
Gross Profit Statutory as reported gross profit was $16.6 million. Pro forma gross profit for the quarter was $15 million, yielding a pro forma gross margin of 62.9% compared to 68% for Q1 2025. The decrease in gross margin was primarily related to tissue versus liquid mix.
Operating Expenses As reported operating expenses for Q1 2026 were $23.9 million, resulting in an as reported operating loss of $7.3 million. On a pro forma basis, excluding the Resolve business, operating expenses were $22.9 million, resulting in a pro forma operating loss of $7.9 million compared to $4.7 million for the prior year. The increase in operating loss was primarily related to the addition of the ExoDx business.
Net Loss Statutory as reported net loss was $8.9 million. Excluding Resolve, pro forma net loss was $9.4 million compared to $9.3 million for Q1 2025.
Cash and Cash Equivalents Cash and cash equivalents as of March 31, 2026, totaled $43.2 million. After a $15 million earn-out payment to Exact Sciences on April 15, pro forma cash as of March 31, 2026, would have been $28.2 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Resolve UTI offering: Discontinued due to reimbursement volatility and operational unsustainability. This decision allows the company to focus on prostate cancer diagnostics.
Prostate cancer diagnostics: Focus on core products like Confirm, GPS, and ExoDx. Transitioned SelectMDx customers to Exo, enhancing operational efficiency.
AI-enhanced diagnostics: Initiated AI-dedicated strategic initiative to build an AI data platform, leveraging biopsy tissue specimens to improve efficiency and clinical value. Collaborating with University of Oxford and a digital innovation company for AI-enhanced offerings.
Prostate cancer diagnostics market: Positioned as a leader in precision diagnostics for urology, offering a comprehensive suite of products for the prostate cancer pathway.
Operational focus: Streamlined operations by exiting the Resolve UTI business and reallocating resources to prostate cancer diagnostics.
Sales force alignment: Completed strategic mapping and cross-training of sales force to focus on prostate cancer diagnostics.
Strategic exit from Resolve UTI: Exited the Resolve UTI business to eliminate reimbursement volatility and focus on scalable prostate cancer diagnostics.
AI-driven innovation: Launched AI initiatives to enhance diagnostics and operational efficiency, including collaborations with University of Oxford and a digital innovation company.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Reimbursement Uncertainty: The company faces significant challenges due to an unexplained policy reversal by Novitas, the Texas Labs Medicare administrator, leading to payer uncertainty. This has resulted in a demand for up to $10.4 million in recoupments of historical Resolve testing claims, which the company is contesting through the Medicare appeals process.
Discontinuation of Resolve UTI Offering: The company decided to discontinue its Resolve UTI offering and cease operations at its Plano, Texas laboratory due to the unsustainable reimbursement landscape. This decision impacts patients who benefited from the test and reflects challenges in maintaining operations amidst reimbursement volatility.
Financial Impact of ExoDx Acquisition: The integration of the ExoDx business has increased operating expenses, contributing to a pro forma operating loss of $7.9 million for the quarter, compared to $4.7 million in the prior year. This highlights the financial strain of integrating new business lines.
Gross Margin Decline: Pro forma gross margin decreased from 68% in Q1 2025 to 62.9% in Q1 2026, primarily due to tissue versus liquid mix. This decline could impact profitability and operational efficiency.
Cash Flow Constraints: The company’s cash and cash equivalents decreased to $28.2 million after a $15 million earn-out payment to Exact Sciences. This reduction in cash reserves could limit financial flexibility for future investments or operations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic exit from Resolve UTI business: The company has decided to discontinue the Resolve UTI offering and cease operations at the Plano, Texas laboratory. This decision was driven by reimbursement uncertainties and a recent policy reversal by Novitas, which created payer uncertainty. The exit allows the company to focus entirely on its core prostate cancer diagnostics business.
Focus on prostate cancer diagnostics: The company is prioritizing its core prostate cancer diagnostics, including Confirm, GPS, and ExoDx. The sales force has been fully aligned and cross-trained to focus on these offerings, aiming to cement the company's position as a leader in urology diagnostics.
AI-driven initiatives: MDxHealth has initiated an AI-dedicated strategic initiative to build an AI data platform. This aims to enhance operating efficiency, maximize clinical value, and optimize customer experience. Collaborations include the PROTECT trial with the University of Oxford and a partnership with a digital innovation company to develop AI-enhanced offerings.
2026 Revenue Guidance: The company has provided updated 2026 revenue guidance for its core cancer business, excluding Resolve, of $110 million to $115 million. This represents a 20% to 26% year-over-year growth rate.
Growth trajectory reset: The strategic exit from the Resolve business is expected to augment the company's ability to drive sustainable and highly profitable growth across its core prostate cancer diagnostics.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the issue with the $10.4 million related to retrospective review of certain historical Resolve mdx claims?
A:The issue is related to a recent development communicated by Novitas. The company anticipates this will not be resolved or adjudicated for a significant period of time unless immediately resolved in their favor. They do not anticipate liability or recoupment, and if any minimal liability arises, it would be amortized over a 5-year period.
Q:Has there been any feedback questioning the clinical utility of the test?
A:The company has not received feedback questioning the clinical utility of the test. They are confident in the medical necessity and clinical validity of their test, which is specifically marketed to urology customers for a specific patient population. They emphasize the test's value and adherence to guidelines.
Q:How did the quarter play out versus expectations, and what is the updated guidance for the rest of the year?
A:The quarter played out as expected, with strong growth in liquid and challenges in tissue due to tough comparisons. The updated guidance reflects adjustments, primarily stripping out expectations for Resolve's contribution. The company remains confident in their core cancer business and anticipates benefits from focusing their sales organization.
Q:What is the cash situation regarding restructuring expenses?
A:The company expects the operation to cease by the end of June. While there will be severance payments and lease charges, they anticipate considerable offsets through efficiencies across the organization. They are confident in materially offsetting the cash outlay.
Q:What are the expenses associated with Resolve, and how easy will it be to eliminate operating expenses?
A:The expenses mainly include incentive compensation for the sales organization. The company expects the majority of costs associated with closing the operation to be offset by organizational efficiencies. While operating expenses will not change materially, some benefits are expected.
Q:Why has tissue volume been declining, and what is being done to address it?
A:The decline in tissue volume is attributed to multifactorial impacts, including integration challenges and customer focus. The company expects sequential acceleration in tissue volume, supported by mapping customer base, utilization rates, and addressing churn. They are confident in their guidance and anticipate improvement.
Q:Did the company receive a noncoverage determination from Novitas, and is coverage suspended?
A:The company did not receive a noncoverage determination from Novitas. Novitas does not have a clear coverage policy for UTI testing, unlike MolDX. The company has followed AMA guidelines and Medicare billing practices for the past 5 years.
Q:Did the company evaluate running the test from a different lab in a Medicare jurisdiction with coverage?
A:The company did not provide specific comments on evaluating running the test from a different lab. They mentioned their Irvine laboratory is under MolDX, which has a noncoverage decision for UTI tests.
Q:Are there any changes in the competitive landscape for tissue volume?
A:There are no material changes in the competitive landscape for GPS. However, there is increased awareness and communication about the promise of AI in the space. The company has partnered with a relevant AI provider and is confident in their approach to support their GPS and Confirm business.
Q:What initiatives are being taken to accelerate tissue volume?
A:The company is focusing on sales execution and leveraging their partnership with an AI provider that serves their common customer base. They are confident that these efforts, along with their operational focus, will drive tissue volume acceleration.
Q:Review of Unclear Management Responses
A:Management avoided directly answering whether they evaluated running the test from a different lab in a Medicare jurisdiction with coverage. They also provided vague responses regarding the timeline for resolving the $10.4 million issue and the specific impacts of restructuring expenses.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI efficiency
AI endpoint
AI initiative
AI offering
AI platform
Exo mapping
ExoDx Exo
ExoDx core
ExoDx integration
ExoDx loss
Francis sir
GPS ExoDx
IFRS result
Laboratory investor
Labs Medicare
Medicare administrator
Plano
Texas
addition
collaboration
core prostate
decision
earn payment
evidence
forma basis
forma loss
loss forma
position
precision diagnostics
principle
reimbursement
responsibility
testing
thousand
view
MDXH Transcript
MDxHealth SA (MDXH) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call reveals several concerning factors: a widening operating loss, a significant net loss, and a decrease in cash reserves. Although management expressed confidence in their core business and provided optimistic guidance, the Q&A highlighted unresolved financial issues and vague responses from management. These factors, combined with the absence of strong positive catalysts, suggest a negative sentiment, likely resulting in a stock price decline of -2% to -8% over the next two weeks.
MDxHealth SA (MDXH) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call presents a mixed picture. Positive elements include revenue growth, improved gross margins, and strategic plans for sales expansion and operational efficiency. However, concerns arise from increased operating losses, complex integration of ExoDx, and lack of specific guidance details. Q&A insights highlight management's confidence in growth but also reveal uncertainties in achieving financial targets. The market may react cautiously, balancing optimism about strategic initiatives with concerns over financial health and execution risks. Given these factors, a neutral stock price movement is anticipated.
MDxHealth SA (MDXH) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call presents a generally positive outlook, with a notable decrease in operating and net losses, and strong cash reserves. The Q&A highlights confidence in Exo's future contributions and sustained performance in GPS and Confirm products. Despite some avoidance in addressing ASP declines, the strategic focus on Exo and sales team expansion suggests growth potential. The absence of material negative factors and optimistic guidance point towards a positive stock price movement in the near term.
MDxHealth SA (MDXH) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call presents a mixed picture: strong revenue growth and improved gross margins are offset by increased net losses and significant financial obligations. The absence of a share repurchase program and concerns over sustaining growth in a competitive market further temper positive sentiment. While management's optimistic guidance and effective market strategy are promising, the lack of specific guidance and financial challenges maintain a neutral outlook for the stock price in the near term.
MDXH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
